A Trial to Evaluate the Efficacy of PRM-151 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

PHASE2CompletedINTERVENTIONAL
Enrollment

117

Participants

Timeline

Start Date

September 1, 2015

Primary Completion Date

May 2, 2017

Study Completion Date

May 2, 2017

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
BIOLOGICAL

PRM-151

PRM 151 10 mg/kg IV infusion over 60 minutes days 1, 3, and 5, then one infusion every 4 weeks

OTHER

placebo

Placebo IV infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks

Trial Locations (18)

14059

Thomayer Hospital, Prague

20900

Azienda Ospedaliera San Gerardo, Monza

22042

Inova Fairfax Hospital, Falls Church

40202

University of Louisville Hospital, Louisville

53715

University of Wisconsin-Madison, Madison

66160

University of Kansas Medical Center, Kansas City

75930

UT - Southwestern Medical School, Dallas

80206

National Jewish Medical and Research Center, Denver

94143

UCSF Interstitial Lung Disease Program, San Francisco

98195

University of Washington Medical Center, Seattle

06520

Yale University School of Medicine, New Haven

02114

Massachusetts General Hospital, Boston

D-35392

Justus-Liebig University Giessen, Giessen

D-69126

Thoraxklinik University of Heidelberg, Heidelberg

78-95123

Az. Ospedaliera Universitaria-Policlinico V. Emanuele di Catania, Catania

3015 CE

Erasmus Medical Center, Rotterdam

08907

Hospital University de Bellvitge, Barcelona

CH-1011

Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02550873 - A Trial to Evaluate the Efficacy of PRM-151 in Subjects With Idiopathic Pulmonary Fibrosis (IPF) | Biotech Hunter | Biotech Hunter